ANIP
ANI Pharmaceuticals, Inc. NASDAQ Listed May 5, 2000$84.20
Mkt Cap $1.9B
52w Low $56.71
64.2% of range
52w High $99.50
50d MA $76.91
200d MA $82.94
P/E (TTM)
23.0x
EV/EBITDA
7.8x
P/B
3.0x
Debt/Equity
0.6x
ROE
14.5%
P/FCF
9.2x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$76.91
200d MA
$82.94
Avg Volume
360.0K
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
210 Main Street West · Baudette, MN 56623 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | 1.99 | 2.33 | +17.1% | 73.90 | +0.1% | +1.8% | +3.0% | +3.6% | +2.3% | +0.2% | — |
| Nov 7, 2025 | AMC | 1.74 | 2.04 | +17.2% | 90.43 | -3.2% | -1.7% | -2.1% | -3.5% | -6.5% | -7.1% | — |
| Aug 8, 2025 | AMC | 1.38 | 1.80 | +30.4% | 81.48 | +0.0% | +4.2% | +8.4% | +8.9% | +10.5% | +7.4% | — |
| May 9, 2025 | AMC | 1.37 | 1.70 | +24.1% | 66.30 | -0.0% | -6.0% | -6.5% | -8.9% | -10.2% | -9.5% | — |
| Feb 28, 2025 | AMC | 1.41 | 1.63 | +15.6% | 61.89 | -1.6% | -5.5% | -4.5% | -3.6% | -1.4% | -2.1% | — |
| Nov 8, 2024 | AMC | 1.09 | 1.34 | +22.9% | 61.44 | +0.1% | +0.5% | -0.7% | -2.6% | -4.1% | -7.9% | — |
| Aug 6, 2024 | AMC | 0.93 | 1.02 | +9.7% | 63.29 | -15.5% | -9.9% | -10.8% | -8.5% | -5.7% | -6.9% | — |
| May 10, 2024 | AMC | 0.98 | 1.21 | +23.5% | 68.05 | -0.5% | -1.0% | -3.0% | -4.7% | -6.3% | -9.7% | — |
| Feb 29, 2024 | AMC | 0.80 | 1.00 | +25.0% | 67.67 | +0.8% | -0.7% | -1.8% | -3.4% | -2.7% | -1.4% | — |
| Nov 8, 2023 | AMC | 0.76 | 1.27 | +67.1% | 54.32 | +1.2% | -3.8% | -4.0% | -4.9% | -2.0% | -3.7% | — |
| Aug 9, 2023 | AMC | 0.64 | 1.28 | +100.0% | 61.08 | +1.2% | -0.8% | +2.6% | +0.0% | +1.3% | -2.8% | — |
| May 8, 2023 | AMC | 0.34 | 1.17 | +244.1% | 42.58 | +2.9% | +4.3% | +2.8% | +3.2% | -2.1% | -4.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16 | Guggenheim | Maintains | Buy → Buy | — | $85.29 | $85.92 | +0.7% | -0.5% | +0.6% | +0.3% | +0.1% | -2.7% |
| Nov 10 | Guggenheim | Maintains | Buy → Buy | — | $90.43 | $87.58 | -3.2% | -1.7% | -2.1% | -3.5% | -6.5% | -7.1% |
| Oct 9 | Truist | Maintains | Hold → Hold | — | $91.65 | $91.65 | +0.0% | -0.9% | -2.0% | -3.3% | -3.2% | -1.7% |
| Sep 24 | JP Morgan | Maintains | Overweight → Overweight | — | $95.33 | $96.41 | +1.1% | -0.4% | -2.1% | -2.4% | -3.6% | -3.9% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $97.55 | $98.18 | +0.6% | -2.2% | -0.1% | -0.8% | -1.7% | -2.3% |
| Sep 8 | Guggenheim | Maintains | Buy → Buy | — | $95.35 | $95.85 | +0.5% | -0.2% | +3.3% | +2.2% | +3.5% | +2.5% |
| Aug 11 | Truist | Maintains | Hold → Hold | — | $81.48 | $81.50 | +0.0% | +4.2% | +8.4% | +8.9% | +10.5% | +7.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.01 | $77.86 | +12.8% | +18.1% | +23.0% | +28.0% | +28.6% | +30.4% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $66.30 | $66.28 | -0.0% | -6.0% | -6.5% | -8.9% | -10.2% | -9.5% |
| Apr 21 | Truist | Maintains | Hold → Hold | — | $69.21 | $69.16 | -0.1% | -1.7% | -0.4% | -1.2% | +0.6% | +0.9% |
| Apr 11 | Guggenheim | Maintains | Buy → Buy | — | $65.12 | $65.45 | +0.5% | +4.6% | +5.5% | +6.8% | +6.3% | +6.3% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.49 | $62.81 | +0.5% | +3.0% | +2.8% | +3.8% | +3.0% | +2.8% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $59.13 | $59.14 | +0.0% | +0.9% | +3.2% | +2.5% | -0.5% | +3.8% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.89 | $60.89 | -1.6% | -5.5% | -4.5% | -3.6% | -1.4% | -2.1% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.44 | $61.53 | +0.1% | +0.5% | -0.7% | -2.6% | -4.1% | -7.9% |
| Oct 22 | Truist | Maintains | Hold → Hold | — | $59.28 | $58.95 | -0.6% | +1.3% | -0.4% | +0.0% | -1.6% | -2.2% |
| Sep 18 | Raymond James | Maintains | Outperform → Outperform | — | $60.06 | $60.46 | +0.7% | +1.6% | +0.5% | -0.7% | +0.0% | -2.6% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.20 | $57.05 | +1.5% | +6.9% | +8.6% | +7.4% | +6.2% | +6.9% |
| Sep 11 | Truist | Downgrade | Buy → Hold | — | $55.48 | $53.51 | -3.6% | -2.1% | +1.2% | +5.5% | +1.3% | +8.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.29 | $53.51 | -15.5% | -9.9% | -10.8% | -8.5% | -5.7% | -6.9% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.19 | $65.29 | +1.7% | +2.0% | -1.7% | -0.8% | -1.2% | -2.4% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.05 | $67.69 | -0.5% | -1.0% | -3.0% | -4.7% | -6.3% | -9.7% |
| Apr 23 | Guggenheim | Maintains | Buy → Buy | — | $65.62 | $65.90 | +0.4% | +0.8% | -0.3% | -1.0% | -0.4% | -0.2% |
| Mar 5 | Guggenheim | Maintains | Buy → Buy | — | $66.42 | $66.59 | +0.3% | -1.6% | -0.9% | +0.4% | +1.5% | -0.4% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.17 | $67.00 | -0.3% | -1.1% | -2.7% | -2.0% | -0.7% | +0.4% |
| Mar 1 | Truist | Maintains | Buy → Buy | — | $67.67 | $68.24 | +0.8% | -0.7% | -1.8% | -3.4% | -2.7% | -1.4% |
| Feb 16 | Truist | Maintains | Buy → Buy | — | $57.55 | $57.98 | +0.7% | +3.8% | +1.4% | +0.1% | +1.0% | +2.7% |
| Oct 19 | Guggenheim | Maintains | Buy → Buy | — | $57.39 | $57.21 | -0.3% | -0.1% | +0.1% | -0.9% | +1.2% | +2.8% |
| Sep 13 | Guggenheim | Maintains | Buy → Buy | — | $61.91 | $61.97 | +0.1% | +1.5% | +2.7% | +0.8% | -0.8% | -1.3% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.21 | $61.59 | +0.6% | +2.1% | +4.2% | +3.5% | +4.2% | +2.5% |
| Aug 21 | Truist | Maintains | Buy → Buy | — | $59.69 | $58.90 | -1.3% | +2.5% | +4.7% | +6.9% | +6.1% | +6.9% |
| Aug 10 | Guggenheim | Maintains | Buy → Buy | — | $61.08 | $61.83 | +1.2% | -0.8% | +2.6% | +0.0% | +1.3% | -2.8% |
| Jul 27 | Guggenheim | Maintains | Buy → Buy | — | $52.19 | $52.57 | +0.7% | -1.2% | +0.3% | +0.7% | -2.7% | -2.0% |
| Jul 21 | Truist | Maintains | Buy → Buy | — | $51.68 | $52.10 | +0.8% | +1.0% | +2.1% | +2.1% | +1.0% | -0.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | +2.8% | +3.2% | -2.1% | -4.0% |
| May 9 | Truist | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | +2.8% | +3.2% | -2.1% | -4.0% |
| May 9 | Raymond James | Maintains | Outperform → Outperform | — | $42.58 | $43.83 | +2.9% | +4.3% | +2.8% | +3.2% | -2.1% | -4.0% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $42.58 | $43.83 | +2.9% | +4.3% | +2.8% | +3.2% | -2.1% | -4.0% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.86 | $40.84 | -0.0% | +0.4% | -0.8% | -2.1% | -2.7% | -3.7% |
| Mar 1 | Guggenheim | Maintains | Buy → Buy | — | $41.84 | $43.18 | +3.2% | +4.7% | +6.1% | +8.7% | +6.2% | +5.7% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.08 | $43.08 | +0.0% | -6.6% | -4.8% | -4.3% | -4.5% | -2.9% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.94 | $35.45 | +1.5% | +6.3% | +7.6% | +6.2% | +4.2% | +3.2% |
| Aug 9 | Raymond James | Maintains | Outperform → Outperform | — | $34.87 | $34.98 | +0.3% | -2.5% | +0.3% | +1.5% | +7.5% | +8.5% |
| Mar 16 | Raymond James | Maintains | Outperform → Outperform | — | $29.01 | $28.06 | -3.3% | -7.3% | -2.4% | -6.1% | -7.2% | -5.3% |
| Nov 2 | Truist | Maintains | Buy → Buy | — | $55.89 | $55.42 | -0.8% | +1.7% | +1.4% | -10.5% | -10.5% | -10.4% |
| Nov 2 | Raymond James | Maintains | Outperform → Outperform | — | $55.89 | $55.42 | -0.8% | +1.7% | +1.4% | -10.5% | -10.5% | -10.4% |
| May 10 | Raymond James | Maintains | Outperform → Outperform | — | $38.60 | $39.23 | +1.6% | -14.8% | -13.9% | -13.1% | -13.1% | -9.2% |
| Aug 3 | Raymond James | Maintains | Outperform → Outperform | — | $29.61 | $29.56 | -0.2% | +0.8% | +4.2% | +4.7% | -0.4% | +2.6% |
| May 8 | Raymond James | Maintains | Outperform → Outperform | — | $34.06 | $33.98 | -0.2% | +0.9% | +2.2% | -4.6% | -8.5% | -11.2% |
| May 7 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $36.96 | $40.62 | +9.9% | -7.8% | -7.0% | -5.8% | -12.1% | -15.7% |
No insider trades available.
8-K · 2.02
!! High
ANI Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
ANI Pharmaceuticals reported Q1 2026 earnings on May 8, 2026, though specific financial metrics require reviewing the full press release to assess investor impact.
May 8
8-K · 4.01
!!! Very High
Unknown — 8-K 4.01: Auditor Change / Resignation
ANIP's auditor switch from EisnerAmper to Ernst & Young suggests potential cost optimization or growth, but investors should verify if any audit disagreements prompted the change, which could signal hidden financial issues.
Apr 7
8-K · 7.01
! Medium
ANI Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
ANI Pharmaceuticals updated its investor presentation for use in ongoing investor and analyst meetings, providing stakeholders with current company information and financial guidance.
Mar 3
8-K
ANI Pharmaceuticals, Inc. -- 8-K Filing
ANI Pharmaceuticals reported strong Q4 2025 results and is strategically pivoting toward rare disease focus while maintaining its generics business, positioning for accelerated growth in 2026.
Feb 27
Data updated apr 24, 2026 6:11pm
· Source: massive.com